BioSpace News Archive

Business

Theravance Biopharma Reports Third Quarter 2017 Financial Results and Provides Business Update

Revenue for the third quarter of 2017 was $4.3M.

November 7, 2017
·
19 min read
Business

Cumberland Pharma Reports 27% Revenue Growth in the Third Quarter

Cumberland Pharma announced third quarter 2017 financial results with Net Revenues of $11.2M, up 27% over the prior year quarter.

November 7, 2017
·
33 min read
Business

Halozyme Reports Third Quarter 2017 Results

Halozyme today reported financial results and recent highlights for the third quarter ended September 30.

November 7, 2017
·
16 min read
Business

DelMar Pharma Appoints Saiid Zarrabian as Interim Chief Executive Officer

Mr. Zarrabian is a highly successful industry veteran.

November 7, 2017
·
5 min read
Business

BioAmber Announces Third Quarter 2017 Financial Results

Sales of bio-succinic acid were $3.3M, compared to $3.7M in Q3 2016.

November 7, 2017
·
19 min read
Business

Syndax Pharma Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update

As of September 30, 2017, Syndax had $120.6M in cash, cash equivalents and short-term investments.

November 7, 2017
·
17 min read
Business

Jazz Pharma Announces Third Quarter 2017 Financial Results

GAAP net income for the third quarter of 2017 was $63.5M, or $1.03 per diluted share, compared to $89.8M, or $1.45 per diluted share, for the third quarter of 2016.

November 7, 2017
·
46 min read
Business

Penumbra Reports Third Quarter 2017 Financial Results

Revenue of $83.9M in the third quarter of 2017, an increase of 24.9%, or 24.1% in constant currency1, over the third quarter of 2016.

November 7, 2017
·
21 min read
Business

Regulus Reports Third Quarter 2017 Financial Results and Recent Events

Regulus Therapeutics today summarized recent events and reported financial results for the three and nine months ended September 30, 2017.

November 7, 2017
·
10 min read
Business

Nektar Therapeutics Reports Financial Results for the Third Quarter of 2017

Cash and investments in marketable securities at September 30, 2017 were $412.2M as compared to $389.1M at December 31, 2016.

November 7, 2017
·
26 min read